Cargando…

The association of serum IL-33/ST2 expression with hepatocellular carcinoma

BACKGROUND: IL-33 is a multifunctional cytokine with dual functions. However, the clinicopathological and prognostic significance of IL-33 in cancer patients, especially in patients with hepatocellular carcinoma (HCC), remains controversial. Therefore, we conducted a study of 565 patients with HCC a...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Xiaolan, Liu, Jinfeng, Li, Meiqin, Liang, Yihua, Liu, Zhimin, Lao, Ming, Fang, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375617/
https://www.ncbi.nlm.nih.gov/pubmed/37507682
http://dx.doi.org/10.1186/s12885-023-11179-5
_version_ 1785079071895453696
author Pan, Xiaolan
Liu, Jinfeng
Li, Meiqin
Liang, Yihua
Liu, Zhimin
Lao, Ming
Fang, Min
author_facet Pan, Xiaolan
Liu, Jinfeng
Li, Meiqin
Liang, Yihua
Liu, Zhimin
Lao, Ming
Fang, Min
author_sort Pan, Xiaolan
collection PubMed
description BACKGROUND: IL-33 is a multifunctional cytokine with dual functions. However, the clinicopathological and prognostic significance of IL-33 in cancer patients, especially in patients with hepatocellular carcinoma (HCC), remains controversial. Therefore, we conducted a study of 565 patients with HCC and 561 healthy controls and performed a meta-analysis to quantitatively evaluate the above problems. METHODS: We collected blood from 565 patients with HCC and 561 healthy controls. ELISA was used to detect the concentrations of IL-33 and ST2 in the serum, and RT‒PCR was used to detect the levels of IL-33 and ST2 mRNA. Meanwhile, we collected comprehensive literature on IL-33 and the clinical characteristics of cancer patients retrieved from the PubMed, Web of Science and CNKI databases as of December 2022. An odds ratio (OR) with a 95% confidence interval (CI) was used to estimate the impact through overall and stratified analyses. RESULTS: Compared with the healthy control group, the levels of ST2 mRNA and serum in the peripheral blood of HCC patients increased (p < 0.05), while the levels of IL-33 mRNA and serum showed no significant difference between the two groups (p > 0.05). In the meta-analysis section, at the tissue level, the overall analysis showed that the expression of IL-33 was positively correlated with tumor stage, histological grade, distant metastasis, and tumor size. Compared with patients with low IL-33 expression, the 3-year overall survival (OS) rate (OR = 3.467, p < 0.001) and 5-year OS rate (OR = 2.784, p < 0.001) of patients with high IL-33 expression were lower. At the serum expression level, the overall analysis showed that the expression of IL-33 increased the risk of cancer, and the serum level of IL-33 was positively correlated with tumor stage and vascular invasion. CONCLUSION: IL-33/ST2 is a useful predictive or prognostic biomarker in clinical evaluation and may be used as a potential therapeutic target, but much research is needed to verify this hypothesis.
format Online
Article
Text
id pubmed-10375617
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103756172023-07-29 The association of serum IL-33/ST2 expression with hepatocellular carcinoma Pan, Xiaolan Liu, Jinfeng Li, Meiqin Liang, Yihua Liu, Zhimin Lao, Ming Fang, Min BMC Cancer Research BACKGROUND: IL-33 is a multifunctional cytokine with dual functions. However, the clinicopathological and prognostic significance of IL-33 in cancer patients, especially in patients with hepatocellular carcinoma (HCC), remains controversial. Therefore, we conducted a study of 565 patients with HCC and 561 healthy controls and performed a meta-analysis to quantitatively evaluate the above problems. METHODS: We collected blood from 565 patients with HCC and 561 healthy controls. ELISA was used to detect the concentrations of IL-33 and ST2 in the serum, and RT‒PCR was used to detect the levels of IL-33 and ST2 mRNA. Meanwhile, we collected comprehensive literature on IL-33 and the clinical characteristics of cancer patients retrieved from the PubMed, Web of Science and CNKI databases as of December 2022. An odds ratio (OR) with a 95% confidence interval (CI) was used to estimate the impact through overall and stratified analyses. RESULTS: Compared with the healthy control group, the levels of ST2 mRNA and serum in the peripheral blood of HCC patients increased (p < 0.05), while the levels of IL-33 mRNA and serum showed no significant difference between the two groups (p > 0.05). In the meta-analysis section, at the tissue level, the overall analysis showed that the expression of IL-33 was positively correlated with tumor stage, histological grade, distant metastasis, and tumor size. Compared with patients with low IL-33 expression, the 3-year overall survival (OS) rate (OR = 3.467, p < 0.001) and 5-year OS rate (OR = 2.784, p < 0.001) of patients with high IL-33 expression were lower. At the serum expression level, the overall analysis showed that the expression of IL-33 increased the risk of cancer, and the serum level of IL-33 was positively correlated with tumor stage and vascular invasion. CONCLUSION: IL-33/ST2 is a useful predictive or prognostic biomarker in clinical evaluation and may be used as a potential therapeutic target, but much research is needed to verify this hypothesis. BioMed Central 2023-07-28 /pmc/articles/PMC10375617/ /pubmed/37507682 http://dx.doi.org/10.1186/s12885-023-11179-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Pan, Xiaolan
Liu, Jinfeng
Li, Meiqin
Liang, Yihua
Liu, Zhimin
Lao, Ming
Fang, Min
The association of serum IL-33/ST2 expression with hepatocellular carcinoma
title The association of serum IL-33/ST2 expression with hepatocellular carcinoma
title_full The association of serum IL-33/ST2 expression with hepatocellular carcinoma
title_fullStr The association of serum IL-33/ST2 expression with hepatocellular carcinoma
title_full_unstemmed The association of serum IL-33/ST2 expression with hepatocellular carcinoma
title_short The association of serum IL-33/ST2 expression with hepatocellular carcinoma
title_sort association of serum il-33/st2 expression with hepatocellular carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375617/
https://www.ncbi.nlm.nih.gov/pubmed/37507682
http://dx.doi.org/10.1186/s12885-023-11179-5
work_keys_str_mv AT panxiaolan theassociationofserumil33st2expressionwithhepatocellularcarcinoma
AT liujinfeng theassociationofserumil33st2expressionwithhepatocellularcarcinoma
AT limeiqin theassociationofserumil33st2expressionwithhepatocellularcarcinoma
AT liangyihua theassociationofserumil33st2expressionwithhepatocellularcarcinoma
AT liuzhimin theassociationofserumil33st2expressionwithhepatocellularcarcinoma
AT laoming theassociationofserumil33st2expressionwithhepatocellularcarcinoma
AT fangmin theassociationofserumil33st2expressionwithhepatocellularcarcinoma
AT panxiaolan associationofserumil33st2expressionwithhepatocellularcarcinoma
AT liujinfeng associationofserumil33st2expressionwithhepatocellularcarcinoma
AT limeiqin associationofserumil33st2expressionwithhepatocellularcarcinoma
AT liangyihua associationofserumil33st2expressionwithhepatocellularcarcinoma
AT liuzhimin associationofserumil33st2expressionwithhepatocellularcarcinoma
AT laoming associationofserumil33st2expressionwithhepatocellularcarcinoma
AT fangmin associationofserumil33st2expressionwithhepatocellularcarcinoma